EE05026B1 - Fulvestrandi kasutamine resistentse rinnav„hi ravis - Google Patents

Fulvestrandi kasutamine resistentse rinnav„hi ravis

Info

Publication number
EE05026B1
EE05026B1 EEP200200574A EEP200200574A EE05026B1 EE 05026 B1 EE05026 B1 EE 05026B1 EE P200200574 A EEP200200574 A EE P200200574A EE P200200574 A EEP200200574 A EE P200200574A EE 05026 B1 EE05026 B1 EE 05026B1
Authority
EE
Estonia
Prior art keywords
fulvestrant
treatment
breast cancer
resistant breast
resistant
Prior art date
Application number
EEP200200574A
Other languages
English (en)
Estonian (et)
Inventor
Thurlimann Beat
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05026(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200200574A publication Critical patent/EE200200574A/xx
Publication of EE05026B1 publication Critical patent/EE05026B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200200574A 2000-04-05 2001-04-02 Fulvestrandi kasutamine resistentse rinnav„hi ravis EE05026B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008172.9A GB0008172D0 (en) 2000-04-05 2000-04-05 Therapy
PCT/GB2001/001500 WO2001074366A1 (en) 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer

Publications (2)

Publication Number Publication Date
EE200200574A EE200200574A (et) 2004-04-15
EE05026B1 true EE05026B1 (et) 2008-06-16

Family

ID=9889101

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200574A EE05026B1 (et) 2000-04-05 2001-04-02 Fulvestrandi kasutamine resistentse rinnav„hi ravis

Country Status (28)

Country Link
US (2) US20030158166A1 (enExample)
EP (2) EP1272195B1 (enExample)
JP (1) JP2003528919A (enExample)
KR (1) KR100757764B1 (enExample)
CN (1) CN1431905A (enExample)
AT (1) ATE306270T1 (enExample)
AU (2) AU2001244372B2 (enExample)
BR (1) BR0109789A (enExample)
CA (1) CA2403608A1 (enExample)
CH (1) CH1272195H1 (enExample)
CZ (1) CZ303096B6 (enExample)
DE (1) DE60113975T2 (enExample)
DK (1) DK1272195T3 (enExample)
EE (1) EE05026B1 (enExample)
ES (1) ES2248300T3 (enExample)
GB (1) GB0008172D0 (enExample)
HU (1) HU230064B1 (enExample)
IL (2) IL151932A0 (enExample)
IS (1) IS2869B (enExample)
MX (1) MXPA02009744A (enExample)
NO (1) NO329949B1 (enExample)
NZ (1) NZ539603A (enExample)
PL (1) PL201175B1 (enExample)
RU (1) RU2265438C2 (enExample)
SK (1) SK287779B6 (enExample)
UA (1) UA80388C2 (enExample)
WO (1) WO2001074366A1 (enExample)
ZA (1) ZA200207538B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
CA2453111A1 (en) * 2001-07-07 2003-01-23 Alan Marshall Irving Pharmaceutical formulation for the intramuscular administration of fulvestrant
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
WO2007062093A2 (en) * 2005-11-22 2007-05-31 Incyte Corporation Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
US20140161827A1 (en) * 2011-05-09 2014-06-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer
CA2836831C (en) 2011-05-20 2015-06-02 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
US20160375234A1 (en) * 2014-01-10 2016-12-29 Atossa Genetic Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
SG11202002105WA (en) 2017-09-11 2020-04-29 Atossa Therapeutics Inc Methods for making and using endoxifen
WO2019224790A2 (en) * 2018-05-24 2019-11-28 Kashiv Biosciences, Llc Prodrugs of fulvestrant
JP7662204B2 (ja) 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
EP4110344A4 (en) * 2020-02-29 2024-03-13 The University Of Vermont Use of thyromimetics for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Also Published As

Publication number Publication date
MXPA02009744A (es) 2004-02-26
HU230064B1 (hu) 2015-06-29
SK287779B6 (sk) 2011-09-05
DK1272195T3 (da) 2006-01-16
HUP0300339A2 (hu) 2003-06-28
PL201175B1 (pl) 2009-03-31
KR20030007501A (ko) 2003-01-23
WO2001074366A1 (en) 2001-10-11
CN1431905A (zh) 2003-07-23
AU4437201A (en) 2001-10-15
CZ303096B6 (cs) 2012-04-04
ZA200207538B (en) 2003-12-19
NZ539603A (en) 2008-02-29
SK14292002A3 (sk) 2003-08-05
DE60113975T2 (de) 2006-06-22
EP1586323A1 (en) 2005-10-19
JP2003528919A (ja) 2003-09-30
ATE306270T1 (de) 2005-10-15
RU2265438C2 (ru) 2005-12-10
ES2248300T3 (es) 2006-03-16
CH1272195H1 (enExample) 2019-10-15
NO20024735D0 (no) 2002-10-02
HK1051498A1 (en) 2003-08-08
EP1272195B1 (en) 2005-10-12
PL357936A1 (en) 2004-08-09
IL151932A0 (en) 2003-04-10
US20110183949A1 (en) 2011-07-28
NO329949B1 (no) 2011-01-31
AU2001244372B2 (en) 2006-02-16
EE200200574A (et) 2004-04-15
GB0008172D0 (en) 2000-05-24
DE60113975D1 (de) 2006-02-23
IS2869B (is) 2014-03-15
IL151932A (en) 2007-07-04
NO20024735L (no) 2002-11-27
CZ20023309A3 (cs) 2003-02-12
UA80388C2 (en) 2007-09-25
US20030158166A1 (en) 2003-08-21
EP1272195A1 (en) 2003-01-08
CA2403608A1 (en) 2001-10-11
KR100757764B1 (ko) 2007-09-12
IS6576A (is) 2002-10-01
HUP0300339A3 (en) 2009-01-28
BR0109789A (pt) 2003-01-21

Similar Documents

Publication Publication Date Title
ATE430570T1 (de) Synergistische kombinationstherapie zur krebsbehandlung
EE200200574A (et) Fulvestrandi kasutamine resistentse rinnavähi ravis
KR970704430A (ko) 전립선 질환, 자궁내막증 및 비만증의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of prostatic diseases endometriosis and obesity)
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
FR08C0013I2 (fr) Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer
ATE305306T1 (de) Reboxetin zur behandlung von peripheren neuropathien
BRPI0407305A (pt) Ligantes do receptor de canabinóides e seus usos
DE602004023342D1 (de) Siliconzusammensetzung und diese enthaltendes Papierbehandlungsmittel
PT1244650E (pt) Derivados arilaminas e sua aplicacao como agentes anti-telomerase
MY138883A (en) Use of asiatic acid for treatment of cencer
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
DE60324431D1 (de) Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs
DE60223576D1 (de) Hautbehandlungszusammensetzung
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
IL161059A0 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
EP1605847A4 (en) Antibody-targeted photodynamic therapy
DE60107034D1 (de) Misch- und Ladeöffnung zur medizinischen Behandlung
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
PL366066A1 (pl) Kompozycje oraz sposoby leczenia i diagnozowania raka sutka
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
NO20005548L (no) Mykobakterieinhibitorer
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
PL354111A1 (en) Combined therapy for treating the both depression and anxiety
EP1646385A4 (en) USE OF BENZOTHIOPHENES TO TREAT AND PREVENT PROSTATE CANCER
NO20010630L (no) Krummet trapp og trappetrinn for krummet trapp

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231